Quan Zhou Shi

Researchers are evaluating the safety and effectiveness of a drug called B007 compared to cyclosporine in treating adults with primary membranous nephropathy, a kidney condition. This study is a multicenter, randomized, controlled, open-label trial conducted in phases II and III to better understand treatment options for this disease. Participants will be randomly assigned to receive either B007 or cyclosporin capsules. B007 is given by subcutaneous injection on days 1 and 15, while cyclosporin capsules are taken orally at a dose of 3.5 mg per kg of body weight per day. The study will observe participants over about two years to assess remission rates and monitor safety. During the trial, participants will undergo laboratory tests and assessments to track overall, complete, and partial remission rates. Researchers will also monitor any treatment-emergent adverse events or serious side effects. Participants must meet specific kidney function criteria and will be followed closely throughout the study period until its completion in late 2026.

Researchers are evaluating the efficacy of Equecabtagene Autoleucel Injection compared to standard therapy in adults with lenalidomide-refractory relapsed or refractory multiple myeloma RRMM who have received one to two prior treatments. This phase III, multicenter, randomized, controlled, open-label study focuses on patients whose disease has progressed despite previous therapies, aiming to better understand treatment options in this condition over about six years. Participants will be assigned randomly to receive either the experimental treatment, Equecabtagene Autoleucel a CAR-T cell therapy targeting BCMA, given as a single injection dose, or standard therapies including combinations of Daratumumab, Bortezomib, Dexamethasone, and Pomalidomide in various regimens. The study involves an initial screening phase followed by treatment and a follow-up phase to monitor safety, treatment effects, and pharmacokinetics. During the study, participants will undergo regular assessments such as laboratory tests, response evaluations, and safety monitoring for up to five years from randomization. Researchers will measure outcomes including progression-free survival, response rates, minimal residual disease negativity, overall survival, and quality of life. The study includes pharmacokinetic and pharmacodynamic monitoring to understand how the experimental treatment behaves in the body.

Researchers are evaluating the use of an artificial intelligence AI system to control anesthesia during painless gastrointestinal endoscopy in adults aged 18 to 65 years with ASA physical status I-II. The study aims to compare the performance of the AI model against anesthesia provided by experienced clinical professionals to see if the AI is not inferior in safely managing anesthesia during the procedure. Participants will be randomly assigned to one of two groups the test group receiving anesthesia controlled by the AI model using ciprofol, and the control group receiving anesthesia induced and maintained by anesthesiologists with ciprofol. Anesthesia induction and maintenance will be closely monitored during the gastrointestinal endoscopy. During the study, participants will fast for 8 hours before the procedure, with no drinking water allowed for 2 hours after taking intestinal purgatives. Researchers will assess outcomes including the incidence of hypoxemia, blood oxygen levels, anesthesia doses and timing, body movements, hypotension, norepinephrine use, procedure duration, and any adverse reactions related to ciprofol. The study includes double-blind monitoring and follows participants through the procedure to evaluate safety and effectiveness measures.